Lundbeck U.S. ranked first among 28 pharmaceutical companies

DEERFIELD - Lundbeck U.S., an affiliate of Danish-based H. Lundbeck A/S, ranked first in corporate reputation among 28 leading U.S. pharmaceutical companies, according to patient groups in PatientView's 4th annual Corporate Reputation of Pharma study.

PatientView's study reflects the views of 106 American patient groups on six key reputational attributes: Patient-Centricity, Information, Patient Safety, Usefulness of Products, Transparency and Integrity. Lundbeck not only ranked first in overall corporate reputation and first in all six individual categories, but received some of the strongest total support in the study's history. According to the report, "the percentages awarded Lundbeck by U.S. patient groups stand among the highest ever recorded in PatientView's Corporate Reputation surveys."

"We are humbled and honored by this recognition from the patient groups whose input determined these study findings," said Peter Anastasiou, president of Lundbeck U.S. "At Lundbeck, patient-centricity is deeply embedded in our culture, and it informs everything we do. We have worked hard to support people living with psychiatric and neurological disorders, and we are very proud of these corporate reputation survey results."

Lundbeck is a global pharmaceutical company specialized in psychiatric and neurological disorders.